Fragile X syndrome is a leading genetic cause of autism. People who have either condition often share certain traits, such as difficulties in social situations.
Many drugs for fragile X syndrome have failed in large clinical trials, but candidates that target new aspects of the condition may fare better.
Autism and intelligence share genetic variants, researchers grow Neanderthal mini-brains and see overlap with autism, and maternal diabetes is an autism risk factor.
Many people with fragile X syndrome show average rates of protein production, challenging a long-held assumption about the condition.
The drug mavoglurant has no effect on a brain circuit involved in social behavior in a mouse model of fragile X syndrome. That may explain its poor performance in people with the condition.
A drug that selectively blocks one form of an enzyme called GSK-3 prevents seizures and improves cognitive deficits in a mouse model of fragile X syndrome.
Our infographic displays efforts to develop treatments for fragile X syndrome. So far, none of them have passed muster in clinical trials.
Watch the complete replay of Sébastien Jacquemont discussing cognitive, behavioral and neural changes underlying the link between genes and conditions such as autism.
The fight over who holds the rights to CRISPR is heating up, we control our gut bacteria, and romance isn’t always easy when you have autism.